Bohui Innovation(SZ:300318) Xin Lang Cai Jing·2026-01-22 08:53Core Viewpoint - The company, 博晖创新, is expected to report a net loss ranging from 117 million to 59 million yuan for 2025, with a non-recurring net loss estimated between 87 million and 44 million yuan, primarily due to declining revenues and increased competition in the market [1] Group 1: Financial Performance - The company's operating revenue has slightly declined year-on-year, with a significant drop in the selling price of HPV products due to the implementation of centralized procurement policies [1] - The net profit attributable to shareholders is expected to be in a loss state, influenced by reduced market demand for certain testing products compared to the same period last year [1] - The gross profit margin has decreased year-on-year, attributed to intensified market competition in the biopharmaceutical sector, leading to lower prices for products such as human albumin and intravenous immunoglobulin [1] Group 2: Operational Challenges - A subsidiary, 博晖生物制药 (河北), incurred a compensation payment of 46 million yuan due to the termination of a business cooperation [1] - Another subsidiary, 廊坊博晖, has resumed production but has not fully recovered in market sales, resulting in continued losses [1] - The company has made provisions for impairment on inventory and development expenses related to HPV testing products due to significant price declines [1] Group 3: Non-Recurring Losses - The expected non-recurring losses for 2025 are estimated to be between -15 million and -30 million yuan, mainly due to the write-off of non-current assets, compensation payments, and government subsidies received [1] - In the previous year, the non-recurring losses were recorded at -308.38 thousand yuan [1]